beta

ADIL

Adial Pharmaceuticals, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Market Cap: 17.4 Million

Primary Exchange: NASDAQ

Website: http://www.adialpharma.com

Shares Outstanding: 10.3 Million

Float: 6.9 Million

Dividend: (%)

Beta: 0.96667096939523

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Longest drawdown: 867 trading days

From: 2019-01-15 To: 2019-12-10

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud